BMAL1-HIF2α heterodimers contribute to ccRCC
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 20 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Kidney cancerThis series is part of our curated briefing on it.
- Samples
- 20 samples: 6 conditions, mostly with about 4 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- BMAL1 and ARNT enable circadian HIF2α responses in clear cell renal cell carcinomaNature communications · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE290669_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1229506 and SRA study SRP566771. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 6 replicated groups read from 20 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8819252 A498 shCNT IP IgG 1 A498 shCNT IP IgG
- GSM8819253 A498 shCNT IP IgG 2 A498 shCNT IP IgG
- GSM8819254 A498 shCNT IP BMAL1 1 A498 shCNT IP BMAL1
- GSM8819255 A498 shCNT IP BMAL1 2 A498 shCNT IP BMAL1
- GSM8819256 A498 shCNT IP BMAL1 3 A498 shCNT IP BMAL1
- GSM8819257 A498 shCNT IP BMAL1 4 A498 shCNT IP BMAL1
- GSM8819258 A498 shCNT IP HIF2a 1 A498 shCNT IP HIF2a
- GSM8819259 A498 shCNT IP HIF2a 2 A498 shCNT IP HIF2a
- GSM8819260 A498 shCNT IP HIF2a 3 A498 shCNT IP HIF2a
- GSM8819261 A498 shCNT IP HIF2a 4 A498 shCNT IP HIF2a
- GSM8819262 A498 shBMAL1 IP IgG 1 A498 shBMAL1 IP IgG
- GSM8819263 A498 shBMAL1 IP IgG 2 A498 shBMAL1 IP IgG
- GSM8819264 A498 shBMAL1 IP BMAL1 1 A498 shBMAL1 IP BMAL1
- GSM8819265 A498 shBMAL1 IP BMAL1 2 A498 shBMAL1 IP BMAL1
- GSM8819266 A498 shBMAL1 IP BMAL1 3 A498 shBMAL1 IP BMAL1
- GSM8819267 A498 shBMAL1 IP BMAL1 4 A498 shBMAL1 IP BMAL1
- GSM8819268 A498 shBMAL1 IP HIF2a 1 A498 shBMAL1 IP HIF2a
- GSM8819269 A498 shBMAL1 IP HIF2a 2 A498 shBMAL1 IP HIF2a
- GSM8819270 A498 shBMAL1 IP HIF2a 3 A498 shBMAL1 IP HIF2a
- GSM8819271 A498 shBMAL1 IP HIF2a 4 A498 shBMAL1 IP HIF2a
- GSE214635 The E3 ligase RBCK1 reduces the sensitivity of ccRCC to sunitinib through the ANKRD35-MITD1-ANXA1 axis 18 samples same disease briefing · shares ccrcc
- GSE17895 Somatic Mutation Screen of Clear Cell RCC 160 samples same disease briefing
- GSE15641 Gene signatures of progression and metastasis in renal cell cancer 92 samples same disease briefing
- GSE22316 PBRM1 Knockdown in RCC Cell Lines 89 samples same disease briefing
- GSE216495 Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma 36 samples same disease briefing
- GSE19982 Gene expression discriminates chromophobe renal cell carcinoma and oncocytoma 30 samples same disease briefing
- GSE216494 Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro 12 samples same disease briefing
- GSE174740 Drug repurposing identifies a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma 11 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.